Showing results (531-540 of 567) with videos related to

Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Diabetes Care|June 26, 2025
Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney DiseaseKevin Yau, Joel G Ray, Nivethika Jeyakumar, et al.
Future Oncology (London, England)|April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancerThomas Powles, Se Hoon Park, Eric Voog, et al.
ESMO Open|December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trialJ E Rosenberg, M D Galsky, T Powles, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Urologic Oncology|January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi studySatya R Khare, Armen Aprikian, Peter Black, et al.
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
BJU International|September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D'Andrea, Surena Matin, Peter C Black, et al.
Pageof 57